2Patricia AG,Kandice KM,Emilio DP,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease.Am J Cardiol,2001,88:230～235.
3Eikelboom JW,Hirsh J,Weit JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events.Circulation,2002,105:1650～1655.
5Patrono C,Coller B,Dalen JE.et al.Platelet-active drugs :the relationships among dose,effectiveness,and side effeets.Chest,1988,114:470～488.
6Cipollone F,Prontera C,Pini B,et al.Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthesis in symptomatic atherosclerotic plague as abasis of prostaglandin E (2)-dependent plaque instability.Circulation,2001,104:921～927.
二级参考文献8
1[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235
2[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B
3[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924
4[4]De Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction.Observations from the TIMI 14 trial[J]. Circulation,2000, 101(3) :239 - 243
5[5]Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲa inhibition: the GUSTO V randomised trial[J]. Lancet, 2001, 357(9272) :1905 - 1914
6[6]Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) - 3 PLUS randomized trial in acute myocardial infarction [J ]. Circulation, 2003, 108(2): 135 - 142
7[7]Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial[J]. Circulation, 2002, 105(14): 1642 - 1649
8[8]Simoons M, Krzeminska - Pakula M, Alonso A, et al.Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study[J].Eur Heart J, 2002, 23 (16) :1282 - 1290
6Baigent C,Sudlow C,Collins R,et al. Collaborative meta-analysis of randomized trials ofantiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. BMJ, 2002,324(7329) :71 - 86.
7Macchi L,Christiaensl L, Brabant S, et al. Resistance to aspirin in vitro is aooociated with increased platelet sensitivity to daenosve diphosphate[ J ]. Thromb Res, 2002,107 (122) : 45 - 49.
8Collaborativemeta-analysis of randomized trials ofantiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. BMJ, 2002,324 : 71- 86.
9Antithrombotic Trialists Collaboration. Collaborative meta analysis of random is edtrial of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [ J ]. Br Med J ,2002,324 (7329) :71-86.
10Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol,2001,88 :230-235.
